EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

The efficacy and safety of selinexor in combination with ruxolitinib in ruxolitinib-treated patients with myelofibrosis: A prospective, multicenter, real-world study

Hongxia Shi, Hong Liang, Shaoling Wu, Qiuling Wu, Jinghua Wang, Hai Lin, Lijun Mu, Hebing Zhou, Hongmei Jing, Minghui Duan

Therapeutic Advances in Hematology · 2026-11 · 17

DOI: 10.1177/20406207261475901 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Hematology, online erschienen am 19.11.2026. Verfasst von Hongxia Shi und 9 weiteren Autor:innen. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ruxolitinib is the standard-of-care treatment for myelofibrosis (MF); however, resistance or intolerance frequently arises. Selinexor, an exportin 1 inhibitor, has demonstrated efficacy in hematologic malignancies.

Objectives

This prospective, multicenter, real-world study assessed the efficacy and safety of selinexor combined with ruxolitinib in ruxolitinib-treated patients with MF.

Design

A Prospective, Multicenter, Real-World Study.

Methods

Patients with MF who were relapsed, had suboptimal response, or intolerance to ruxolitinib, received selinexor plus ruxolitinib. The primary endpoint was spleen response.

Results

As on February 2025, 41 patients received at least one dose of selinexor. The median age was 62 years, and the mean duration of prior ruxolitinib treatment was 20.52 months (range: 3.60–77.04 months). Twenty-seven patients had a splenomegaly length of >5 cm below the rib at baseline. A decrease in spleen length was observed in 23 patients (85.19%), and 15/27 patients (55.56%) reported a spleen response. Symptom alleviation was observed in 35/41 patients (85.37%), with a total symptom score reduction of ≥ 50% in 13 patients (31.71%). At a median follow-up of 24.83 months, the median PFS was 22.90 months and the median OS was not reached. Most common grade 1-2 AEs were nausea, decreased appetite and vomiting.

Conclusion

Selinexor plus ruxolitinib showed promising efficacy and acceptable safety in ruxolitinib-treated patients with MF. Registration Trial registry name: Chinese Clinical Trial Registry, Registration number: M2022167, URL: ( https://itmctr.ccebtcm.org.cn/M2022167 ).

Zitieren

APA

Shi, H., Liang, H., Wu, S., Wu, Q., Wang, J., Lin, H., Mu, L., Zhou, H., Jing, H., & Duan, M. (2026). The efficacy and safety of selinexor in combination with ruxolitinib in ruxolitinib-treated patients with myelofibrosis: A prospective, multicenter, real-world study. Therapeutic Advances in Hematology, 17. https://doi.org/10.1177/20406207261475901

Vancouver

Shi H, Liang H, Wu S, Wu Q, Wang J, Lin H, et al. The efficacy and safety of selinexor in combination with ruxolitinib in ruxolitinib-treated patients with myelofibrosis: A prospective, multicenter, real-world study. Therapeutic Advances in Hematology. 2026;17. doi:10.1177/20406207261475901

BibTeX
@article{Shi2026,
  author = {Shi, Hongxia and Liang, Hong and Wu, Shaoling and Wu, Qiuling and Wang, Jinghua and Lin, Hai and Mu, Lijun and Zhou, Hebing and Jing, Hongmei and Duan, Minghui},
  title = {The efficacy and safety of selinexor in combination with ruxolitinib in ruxolitinib-treated patients with myelofibrosis: A prospective, multicenter, real-world study},
  journal = {Therapeutic Advances in Hematology},
  year = {2026},
  volume = {17},
  doi = {10.1177/20406207261475901}
}
Kostenlos starten →